Pfizer Inc. $PFE Shares Acquired by ABN Amro Investment Solutions

ABN Amro Investment Solutions lifted its holdings in shares of Pfizer Inc. (NYSE:PFE) by 11.9% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 313,794 shares of the biopharmaceutical company’s stock after buying an additional 33,262 shares during the period. ABN Amro Investment Solutions’ holdings in Pfizer were worth $8,811,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of the business. Horizon Financial Services LLC grew its holdings in shares of Pfizer by 174.8% during the fourth quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 645 shares during the last quarter. Godfrey Financial Associates Inc. acquired a new position in Pfizer during the 4th quarter valued at approximately $26,000. YANKCOM Partnership bought a new position in Pfizer during the 4th quarter worth $28,000. HFM Investment Advisors LLC lifted its position in Pfizer by 61.0% in the 4th quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 427 shares during the last quarter. Finally, Evolution Wealth Management Inc. boosted its stake in Pfizer by 132.2% during the 1st quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 566 shares during the period. Institutional investors own 68.36% of the company’s stock.

Pfizer Price Performance

Shares of Pfizer stock opened at $24.84 on Thursday. The company has a current ratio of 1.25, a quick ratio of 0.94 and a debt-to-equity ratio of 0.67. The company’s 50-day moving average price is $25.14 and its two-hundred day moving average price is $26.18. Pfizer Inc. has a 52 week low of $23.11 and a 52 week high of $28.75. The stock has a market cap of $141.60 billion, a PE ratio of 18.97 and a beta of 0.35.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.72 by $0.03. The company had revenue of $14.45 billion during the quarter, compared to analyst estimates of $13.84 billion. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. The business’s revenue for the quarter was up 5.4% on a year-over-year basis. During the same quarter last year, the firm posted $0.92 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, sell-side analysts anticipate that Pfizer Inc. will post 2.96 EPS for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Friday, July 24th will be given a $0.43 dividend. The ex-dividend date is Friday, July 24th. This represents a $1.72 annualized dividend and a yield of 6.9%. Pfizer’s payout ratio is 131.30%.

Wall Street Analyst Weigh In

PFE has been the subject of several analyst reports. Morgan Stanley increased their price objective on Pfizer from $27.00 to $28.00 and gave the stock an “equal weight” rating in a report on Friday, April 10th. UBS Group reaffirmed a “neutral” rating and set a $27.00 target price on shares of Pfizer in a research note on Wednesday, May 27th. Citigroup boosted their price target on Pfizer from $26.00 to $27.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 29th. Wall Street Zen cut Pfizer from a “buy” rating to a “hold” rating in a research note on Saturday, July 4th. Finally, Guggenheim lowered their price target on Pfizer from $36.00 to $35.00 and set a “buy” rating on the stock in a report on Monday, July 13th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have assigned a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, Pfizer presently has an average rating of “Hold” and an average target price of $28.50.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer’s TALZENNA plus XTANDI combination received FDA Priority Review for men with HRR gene-altered metastatic castration-sensitive prostate cancer, which could expand the drug pair’s approved use and support oncology revenue growth if approved. Article Title
• Positive Sentiment: Some commentary highlights Pfizer as an undervalued healthcare name, suggesting investors may be overlooking its earnings power and pipeline optionality. Article Title
• Neutral Sentiment: Analysts are also watching Pfizer’s non-oncology portfolio this earnings season, with expected strength in Eliquis and Vyndaqel offset by continued weakness in COVID-related products. Article Title
• Negative Sentiment: Pfizer is facing expanded patent litigation tied to mRNA lipid nanoparticle technology, adding legal uncertainty around its COVID-19 vaccine business and creating a potential overhang on sentiment. Article Title
• Negative Sentiment: Broader U.S. drug-policy headlines, including proposed tariffs on generic medicines, may keep pressure on the pharmaceutical sector even though the direct impact on Pfizer is less clear than for generic-focused peers. Article Title

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.